Evidilya at EADV Congress 2026: dermatology evidence beyond the trial site
Vienna, 30 September – 3 October. Topical and device-supported treatments, decentralised tolerability programmes, and how quality-of-life endpoints hold up when captured remotely.
Event · · 1 min
Evidilya joins the dermatology community at the EADV Congress 2026 in Vienna, 30 September – 3 October. Our team will be discussing topical and device-supported treatments, decentralised tolerability programmes, and the question that decides most dermatology designs: how quality-of-life and symptom endpoints hold up when they are captured remotely rather than at a visit.
Dermatology is unusually well suited to evidence generation beyond the trial site. Lesions can be imaged, itch and sleep disruption are experienced daily rather than at three-month intervals, and tolerability signals appear in ordinary use long before they appear in a clinic. What changes is the discipline required: standardised image capture, instruments validated for self-completion, and a provenance trail that lets a reviewer see where every observation came from.
If you are in Vienna and working on a dermatology programme, come and talk to us.
Written by the Evidilya scientific team. For interviews, references or a full publication list, use the contact page.
Talk to our team.
Bring us the evidence question you're wrestling with, we'll tell you the shortest defensible path.